His primary scientific interests are in Internal medicine, Oncology, Surgery, Prostate cancer and Renal cell carcinoma. Kidney cancer and Nephrology are subfields of Internal medicine in which his conducts study. His Oncology study incorporates themes from Odds ratio, Cancer and Chemotherapy.
His Surgery research integrates issues from Urology, MEDLINE and Hazard ratio. His work carried out in the field of Prostate cancer brings together such families of science as Biopsy and Risk factor. The study incorporates disciplines such as Carcinoma and Nephrectomy in addition to Renal cell carcinoma.
Peter F.A. Mulders mainly focuses on Internal medicine, Renal cell carcinoma, Oncology, Prostate cancer and Surgery. His biological study deals with issues like Placebo, which deal with fields such as Interim analysis. His Renal cell carcinoma research incorporates elements of Cancer research, Carcinoma and Nephrectomy.
Peter F.A. Mulders interconnects Chemotherapy, Castration resistant, Enzalutamide, Immunology and Immunotherapy in the investigation of issues within Oncology. His research integrates issues of Prostate and Urology in his study of Prostate cancer. His Surgery study often links to related topics such as Hazard ratio.
Peter F.A. Mulders mostly deals with Internal medicine, Prostate cancer, Oncology, Renal cell carcinoma and Clear cell renal cell carcinoma. His study in Internal medicine is interdisciplinary in nature, drawing from both Major depressive disorder and Treatment-resistant depression. His Prostate cancer study combines topics in areas such as Biomarker, Prostate and Surgery.
His Oncology research includes themes of Clinical trial, Enzalutamide, Abiraterone acetate, Survival analysis and Cancer biomarkers. Peter F.A. Mulders has included themes like Radiology and Nephrectomy in his Renal cell carcinoma study. Peter F.A. Mulders focuses mostly in the field of Interim analysis, narrowing it down to matters related to Placebo and, in some cases, Hazard ratio.
The scientist’s investigation covers issues in Internal medicine, Oncology, Prostate cancer, Renal cell carcinoma and Radiology. His study in Abiraterone acetate, Enzalutamide and Survival analysis are all subfields of Internal medicine. His biological study spans a wide range of topics, including Post-hoc analysis, Chemotherapy and Prednisone.
His studies in Prostate cancer integrate themes in fields like Framingham Risk Score and Surgery. His Surgery study integrates concerns from other disciplines, such as Biomarker, Prostate biopsy, Biopsy and PCA3. His Renal cell carcinoma research is multidisciplinary, incorporating perspectives in Kidney and Nephrectomy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin.
The New England Journal of Medicine (2012)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Borje Ljungberg;Karim Bensalah;Steven Canfield;Saeed Dabestani.
European Urology (2010)
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.
Thorgeir E Thorgeirsson;Frank Geller;Patrick Sulem;Thorunn Rafnar.
GuidelinesEAU Guidelines on Renal Cell Carcinoma: The 2010 Update
Börje Ljungberg;Nigel C. Cowan;Damian C. Hanbury;Milan Hora.
European Urology (2010)
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo.
Journal of Clinical Oncology (2005)
SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE
Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck.
The Journal of Urology (2004)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad.
Lancet Oncology (2015)
Renal cell carcinoma guideline.
Börje Ljungberg;Damian C. Hanbury;Marcus A. Kuczyk;Axel S. Merseburger.
European Urology (2007)
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Alexander Haese;Alexandre de la Taille;Hendrik van Poppel;Michael Marberger.
European Urology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: